Compound research

BPC-157
history

Where BPC-157 came from, how it got its name, how three decades of research grew around one laboratory, and how regulators have treated it, dated to November 2026.

Short answerCompound research · 8 min read · Updated 18 Nov 2026

BPC-157’s history starts at the University of Zagreb. A research group there described a gastric juice protein it called BPC in 1992, and a 15-amino-acid fragment of it, BPC 157, in 1993. It was developed under the code PL 14736 in the early 2000s, named by WADA in 2022, and is still not an approved medicine.

Key takeaways

  • A University of Zagreb group described the parent protein, BPC, in 1992 and the 15-amino-acid fragment BPC 157 in 1993; FDA staff say researchers there first synthesised it.
  • BPC stands for body protection compound, the 1992 authors’ name for the parent protein: a label, not a finding about what BPC-157 does. Its codes include PL-10, PLD-116 and PL 14736, and FDA lists the name Bepecin.
  • Of 234 PubMed records naming it, 175 list the Zagreb group’s Pavle Sikirić as an author (our count); the share has fallen to 62 of 109 since 2020.
  • A clinical programme under PL 14736 in 2002–2005 is known only from meeting abstracts, and FDA staff judged its phase II data inadequate.
  • WADA named it in 2022, FDA placed it in Category 2 in 2023, Australia scheduled it in 2024, and in 2026 HHS issued a compounding policy. None is an approval.

01BPC-157 history at a glance

A dated record, from the first paper to November 2026.

DateWhat happened
1992A University of Zagreb group publishes on a “newly partially characterized gastric juice peptide” it calls body protection compound, or BPC. It is the earliest PubMed record we found that names it.
1993The same group describes a 15-amino-acid fragment, BPC 157, as “fully characterized”. FDA staff, 2026: “Literature shows that BPC-157 was first described in 1993.”
2001The phrase “stable gastric pentadecapeptide” first appears in PubMed titles and abstracts about it.
2002–2005Clinical development under the code PL 14736: early safety studies and a phase II trial in ulcerative colitis, reported only as meeting abstracts.
2006A Zagreb paper links BPC 157 to the codes PL-10, PLD-116 and PL 14736 and to Pliva, Croatia.
Dec 2015The first ClinicalTrials.gov record (NCT02637284, phase 1) is posted. Its status is unknown, with no posted results.
2017A US anti-doping laboratory reports BPC 157 identified in confiscated vials and publishes a urine test for it.
30 Sep 2021WADA publishes its 2022 Prohibited List, naming BPC-157 in class S0. It is the first substance named by example in that class. The List takes effect on 1 January 2022.
Sep 2023FDA places BPC-157 in Category 2 of its compounding policies, for bulk substances that may present significant safety risks.
1 Jun 2024Australia: Schedule 4 and Appendix D entries take effect, after the TGA’s final decision of 22 May 2024.
13 Apr 2026A TGA safety advisory lists BPC-157 among examples of unapproved peptide products.
22 Apr 2026BPC-157 leaves Category 2. HHS later notes that neither the placement nor the removal changed its status under section 503A.
23 Jul 2026FDA’s Pharmacy Compounding Advisory Committee votes in favour of adding it to the 503A bulks list. FDA’s drug centre had recommended against. The vote is advice, not a rule.
28 Oct 2026HHS issues an enforcement-discretion policy for compounding BPC-157 acetate by licensed pharmacies and physicians on prescription, under conditions. It is not an approval, and products sold as research chemicals are outside it.
Nov 2026Not an approved medicine. In their 2026 review, a database search by FDA staff found no approved product containing it in any country.

02Where did BPC-157 come from?

BPC-157 began in a pharmacology department at the University of Zagreb, Croatia. In 1992 a group whose papers list Pavle Sikirić as first author described a protein from gastric juice, which it called body protection compound, or BPC. The paper called it “newly partially characterized”. In 1993 the group’s overview reported that this protein, of about 40,000 daltons, had been “recently isolated”, and that a 15-amino-acid fragment, named BPC 157, had been “fully characterized”.

FDA staff, reviewing it in 2026, put it this way: BPC-157 “was first synthesized by researchers at University of Zegreb [sic], Republic of Croatia, in the early 1990s”, and it is “reported to be a pentadecapeptide fragment of BPC” that “has been found in gastric juice”. They add that in 1993 it was described as made by stepwise solid-phase synthesis and purified by HPLC to a purity above 95%. BPC-157 is a synthetic 15-amino-acid peptide.

The first studies were in rats, in models of stomach, duodenal and liver lesions. Those are animal models (T3). They are where the research started, not evidence about people.

03What is BPC-157’s structure?

BPC-157 is a pentadecapeptide: a chain of 15 amino acids. Its sequence, as HHS’s 2026 policy appendix gives it, is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, written in one-letter code as GEPPPGKPADDAGLV.

  • Free base. Formula C62H98N16O22, molecular weight 1,419.5 g/mol (FDA, 2026).
  • Acetate salt. HHS gives 1,419.54 g/mol plus the acetate, and its 2026 policy covers this form.
  • Which form a study used. FDA staff evaluated both, and noted that most studies do not say which form they used.

That matters for anyone reading the literature: a result for one salt form is not automatically a result for another. More: peptide salt forms and how identity is checked by mass spectrometry.

04How did BPC-157 get its name?

BPC. The letters come from the 1992 paper’s name for the parent protein, body protection compound. FDA’s 2026 briefing still opens with that expansion. The name is the authors’ label, not a finding about what the peptide does.

157. The papers we read do not explain the number.

Stable gastric pentadecapeptide. From 2001 the group’s titles and abstracts often call it “stable gastric pentadecapeptide BPC 157”. Of the 118 PubMed records using that phrase, 114 list Sikirić as an author (our count, 18 November 2026).

Development codes. A 2006 paper from the group gives the codes PL-10, PLD-116 and PL 14736, with “Pliva, Croatia”. FDA staff list two other names: “BPC-157 is also known as Bepecin or PL-14736”.

Spelling. The Zagreb papers mostly write “BPC 157”. Regulators and WADA write “BPC-157”. They are the same peptide.

05How did research on BPC-157 develop?

Mostly in one group’s laboratories, and mostly in animals. The share of papers listing that group’s lead author has fallen this decade.

YearsPubMed records naming itWith Pavle Sikirić as an author
1993–19992221
2000–20094239
2010–20196153
2020–18 Nov 202610962
All years234175 (75%)

Our count from a PubMed title and abstract search for BPC-157, BPC 157, BPC157, bepecin, PL 14736 and “pentadecapeptide BPC”, by publication date, run 18 November 2026. The percentage is our calculation.

1990s: one group. 21 of the 22 records list Sikirić as an author.

2002–2005: a clinical programme. Under the code PL 14736, early safety studies and a phase II trial in ulcerative colitis were run. All three are known only from meeting abstracts. FDA staff judged that trial’s data “inadequate to support the efficacy and safety” of BPC-157 as the trial gave it. We found no published phase III trial.

2010s: more animal models. The literature grew, still mostly from Zagreb (53 of 61 records list Sikirić) and mostly in animals, as later reviews found.

2020s: more groups, and reviews. Records this decade already outnumber the 1990s and 2000s together, and 47 of the 109 do not list Sikirić. Independent reviewers have weighed the evidence. A 2025 systematic review of musculoskeletal studies found 35 of its 36 included studies were preclinical. A 2026 systematic review of the three full human papers rated the certainty of the evidence “very low”. In July 2026, FDA staff concluded there is “insufficient clinical safety information to characterize the safety profile” of BPC-157.

Trials. ClinicalTrials.gov lists four records: one first posted in 2015 and three in 2026. None has posted results (18 November 2026). Every study we found that gave it to people: BPC-157 human studies. The evidence today: BPC-157 research guide.

06How have regulators treated BPC-157?

In the record below, sport moved first, in 2021; the medicines-regulator steps start in 2023. In 2026, FDA’s drug centre and its advisory committee disagreed.

Sport. On 30 September 2021 WADA published its 2022 List and wrote: “For the first time, a substance has been included by name as an example in section S0”. That substance was BPC-157, which WADA called “an experimental peptide sold as a supplement”. It is still named in the 2026 and 2027 Lists. Detail: peptides and anti-doping.

United States. HHS’s 2026 policy appendix records that BPC-157 was in Category 2 “from September 2023 until April 22, 2026, and neither the placement nor the removal changed their status under section 503A”. It adds that FDA’s drug centre “recommended against listing either form, and the Pharmacy Compounding Advisory Committee (PCAC) voted in favor of inclusion”. HHS then issued its enforcement-discretion policy in October 2026. None of this is an approval. Full record: is BPC-157 legal? and the 2026 committee vote.

Australia. The TGA scheduled BPC-157 in Schedule 4, prescription-only, and in Appendix D, from 1 June 2024. Its decision notices recorded “no currently approved products containing BPC-157 in Australia”. In April 2026 a TGA advisory listed it first among examples of unapproved peptide products.

Approval. In their July 2026 review, a database search by FDA staff found no approved product containing BPC-157 in any country. More than 30 years after the first paper, it is not an approved medicine.

07What we don’t know about BPC-157’s history

  • The full structure of the parent protein, BPC. The 1992 paper calls it partially characterised, and the papers we read do not give its sequence.
  • What the number 157 stands for.
  • Why the PL 14736 programme stopped. We found no published phase III trial and no statement explaining it.
  • The full results of the early human studies, known only from meeting abstracts.
  • How much of the animal literature independent groups have repeated. Three in four PubMed records list one author from one group.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026 (pp. 7, 13–14, 21, 27); read 18 Nov 2026. www.fda.gov/media/193343/download
  2. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, Appendix B. Policy document, October 2026; hhs.gov returned 403 to our tools, read on the Internet Archive capture of 15 Nov 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  3. World Anti-Doping Agency. WADA publishes 2022 Prohibited List. News release, 30 Sep 2021; read at wada-ama.org 18 Nov 2026. And the 2026 and 2027 Prohibited Lists, class S0. www.wada-ama.org/en/news/wada-publishes-2022-prohibited-list
  4. Therapeutic Goods Administration. Notices of interim (3 Apr 2024) and final (22 May 2024) decisions to amend (or not amend) the current Poisons Standard, ACMS #43 (November 2023), BPC-157. Read on the Internet Archive captures of 6 Nov 2025 and 21 Apr 2025 (tga.gov.au timed out on 18 Nov 2026), as on is-bpc-157-legal-in-australia. www.tga.gov.au/resources/publication/scheduling-decisions-fi…
  5. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 Apr 2026; read on the Internet Archive capture of 10 Aug 2026, the newest. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  6. Sikiric P, Petek M, Rucman R, et al. [Rat study naming the gastric juice peptide body protection compound (BPC).] Acta Physiol Hung, 1992;80(1–4):89–98. PMID 1345210. pubmed.ncbi.nlm.nih.gov/1345210/
  7. Sikirić P, Petek M, Rucman R, et al. [Overview of the gastric juice peptide BPC and its 15-amino-acid fragment, BPC 157.] J Physiol Paris, 1993;87(5):313–327. PMID 8298609. pubmed.ncbi.nlm.nih.gov/8298609/
  8. Sikiric P, Seiwerth S, Brcic L, et al. [Review of BPC 157 naming the development codes PL-10, PLD-116 and PL 14736 and Pliva, Croatia.] Inflammopharmacology, 2006;14(5–6):214–221. PMID 17186181. pubmed.ncbi.nlm.nih.gov/17186181/
  9. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal, 2017;9(10):1490–1498. PMID 28035768. pubmed.ncbi.nlm.nih.gov/28035768/
  10. Vasireddi N, Hahamyan HA, Salata MJ, et al. [Systematic review of musculoskeletal studies of BPC-157.] HSS J, 2025. PMID 40756949. pubmed.ncbi.nlm.nih.gov/40756949/
  11. Poolton JT, Minett J, Kazmi A. [Systematic review of human studies of BPC-157, with certainty ratings.] Acta Orthop Belg, 2026;92(3). PMID 42885452. pubmed.ncbi.nlm.nih.gov/42885452/
  12. ClinicalTrials.gov. Records for BPC-157, BPC 157, BPC157 and bepecin: NCT02637284, NCT07437547, NCT07752381, NCT07803250. Registry search via API v2, 18 Nov 2026. clinicaltrials.gov/search?term=BPC-157
  13. PubMed searches run 18 Nov 2026: BPC-157 names in title or abstract (234 records, grouped by publication date and by author Sikiric P); “stable gastric pentadecapeptide” (118 records, earliest 2001); earliest record naming BPC (1992). Database searches; counts are ours. pubmed.ncbi.nlm.nih.gov/?term=%22BPC-157%22%5Btiab%5D+OR+%22…

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Who discovered BPC-157?

A research group at the University of Zagreb, Croatia, whose 1992 and 1993 papers list Pavle Sikirić as first author. FDA staff say BPC-157 was first synthesised by researchers there in the early 1990s and first described in 1993.

What does BPC stand for in BPC-157?

Body protection compound: the name the Zagreb group gave the parent gastric juice protein in 1992. It is the authors’ label, not a finding about what the peptide does. The papers we read do not explain the number 157.

Is BPC-157 found in the body?

FDA staff describe it as “reported to be” a fragment of a protein found in gastric juice, a protein the 1992 paper called partially characterised. BPC-157 itself is a synthetic 15-amino-acid peptide, which FDA staff say was first synthesised in Zagreb in the early 1990s.

When was BPC-157 banned in sport?

WADA named it in class S0 of its 2022 Prohibited List, published on 30 September 2021 and in force from 1 January 2022. It is still named in the 2026 and 2027 Lists.

Is BPC-157 an approved medicine anywhere?

No. In their 2026 review, a database search by FDA staff found no approved product containing it in any country. The July 2026 committee vote and the October 2026 HHS policy concern compounding on prescription, and neither is an approval.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page